Diligent Launches AI Act Toolkits to Support Organizations in Complying with New EU AI Regulation
Toolkits enable customers to identify AI systems, classify associated risk, ensure compliance with the EU's AI Act obligations and uphold global ethical best practices.
Diligent, a leading GRC SaaS company, today announced the launch of its new Artificial Intelligence (AI) Act Toolkits, designed to help corporate secretaries, legal and compliance teams, chief technology officers, chief information security officers and audit teams navigate the increasing complexity of AI governance and AI regulatory compliance. The Toolkits empower businesses operating inside and outside the European Union (EU) to understand and comply with the requirements of the EU's AI Act, and to integrate a responsible and ethical approach to AI adoption that builds trust in new technologies and adheres to global standards for AI governance.
“As the AI landscape evolves, organizations are challenged to balance innovation with regulatory compliance and ethical considerations,” said Keith Fenner, Senior Vice President & General Manager, International at Diligent. “The EU's AI Act represents a significant regulatory milestone to ensure AI systems are safe, transparent, and respect fundamental rights. We’re thrilled to offer a solution that helps customers identify and map regulatory obligations, implement best practice controls, and govern AI responsibly. This ensures compliance with evolving global regulations while accelerating the adoption of AI technology and delivering value.”
There are three toolkits available within the Diligent One Platform:
- AI Discovery and Risk Classification Toolkit – This toolkit helps customers identify their AI systems and perform the required risk classification exercise. It also provides access to an extensive library of AI literacy and best practice governance resources for the board, senior management and employees to accelerate organizational readiness and elevate AI governance. The toolkit is available to all Diligent One Platform customers.
- AI Act IT Compliance Toolkit – This toolkit helps organizations understand regulatory requirements, map them against suggested controls, and document compliance. It offers suggested control mapping to the AI Act’s regulatory requirements, gap identification, a dashboard summary for control assessment, a remediation summary and notifications to key stakeholders.
- AI Act Risk Management Toolkit – This comprehensive risk management toolkit supports a complete AI governance program. It features a risk heatmap for reviewing and prioritizing risks, a dashboard summarizing AI systems by risk level, a pre-configured AI threat library, and tools for continuous monitoring to ensure policy adherence and compliance.
In a world where, according to surveys, 78% of employees bring their own AI tools to work and 86% of businesses use some form of AI without the board’s awareness, Diligent's AI Act Toolkits are designed to support compliance, governance and risk management efforts. The Toolkits help customers to identify their AI systems and models, apply a risk-based classification, understand their obligations as providers and deployers under the AI Act, build an AI governance framework and monitor ongoing compliance. This helps to ensure that AI systems are implemented responsibly and ethically, and in a manner that documents compliance efforts in accordance with customer, partner, employee and regulator expectations.
Diligent’s Toolkits provide a robust framework for assessing and managing the risks associated with AI systems, helping organizations incorporate ethical considerations into their AI development, and supporting ongoing compliance with the EU’s AI Act. As AI becomes increasingly integral to business strategy, the Toolkits reflect Diligent's dedication to supporting ethical AI practices and helping its customers stay ahead of regulatory changes.
To learn more about the AI Act Toolkits from Diligent, visit: https://www.diligent.com/lp/eu-ai-act-compliance
About Diligent
Diligent is the leading GRC SaaS company, empowering more than 1 million users and 700,000 board members and leaders to make better decisions, faster. The Diligent One Platform helps organizations connect their entire GRC practice — including governance, risk, compliance, audit and ESG — to bring clarity to complex risk, stay ahead of regulatory changes and deliver impactful insights, in one consolidated view. Learn more at diligent.com.
Follow Diligent on LinkedIn, X (Twitter) and Facebook.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240918400561/en/
Contacts
Media
Media
Julia Stoyanov
Communications Director, Diligent
+1 (604) 669-4225
Jhanbury@diligent.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom